eyeball
eyeball
eyeball
eyeball
eyeball
eyeball
eyeball
eyeball

PATIENT WEBSITE LINK:

https://studykik.com/study-page/wamd-19493-hcp

Study Site Locations

Please contact the site closest to you for study inquiries or to discuss a patient referral.

Search within
Miles of

TX

Retina of North Texas

Sai Chavala

11615 Forest Central Drive Suite 308

Dallas

TX

75243

Ranime Belhamidi

214-233-6170

MO

Discover Vision Center

Ajay Singh

4741 South Cochise Drive

Independence

MO

64055

Judy Rosenthal

NC

Graystone Eye - Hickory Office

Thomas Williams

2424 Century Pl SE

Hickory

NC

28602-4031

Brittany Stone

AZ

Retina Macula Institute of Arizona

Mark Barakat

20201 N Scottsdale Healthcare Drive Suite 100

Scottsdale

AZ

85255

Michelle Zunitch

VA

Emerson Clinical Research Institute

Khurram Malik

6565 Arlington Blvd Suite 400

Falls Church

VA

22046

Fatima Ruiz

VA

Virginia Retina Center

Sam Mansour

45 N Hill Dr Ste 202

Warrenton

VA

20186-2677

Amandeep Gill

LA

Retina Associates New Orleans

Gwen Cousins

4315 Houma Blvd Suite 201

Metairie

LA

70006

Amanda Byers

CA

Doctor Retina

Maziar Lalezary

8383 Wilshire Blvd Suite 440

Beverly Hills

CA

90211

Thomas Stanique

AZ

Associated Retina Consultants - Phoenix

Joseph Bryan

1750 E Glendale Ave

Phoenix

AZ

85020

Mallory Mintert

TX

Red River Research Partners, LLC

Hemang Pandya

6000 W Spring Creek Pkwy Suite 215

Plano

TX

75024

John Zamudio

CA

Global Research Management, Inc.

Sherif El Harzai

1510 S Central Ave Suite 300

Glendale

CA

91204

Logi Elharazi

FL

Retina Care Specialists

Paul Gallogly

3399 PGA Blvd. Suite 350

Palm Beach Gardens

FL

33410

Adrienne Ryder

PA

Retina Vitreous Consultants

Deepam Rusia

300 Oxford Drive Suite 300

Monroeville

PA

15146

Lori Merlotti

eye charteye chart

Inclusion and Exclusion Criteria

Patients who meet the following criteria may be eligible to participate: Inclusion • Male or female subjects, ≥50 years of age. • Documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. • Active subfoveal CNV due to wAMD, including juxtafoveal lesions that affect the fovea, as defined by presence of fluid (intraretinal or subretinal) affecting the central subfield as measured by SD-OCT. Exclusion • CNV caused by ocular histoplasmosis, pathological myopia, angioid streaks, choroidal rupture, uveitis, and trauma. • Fibrosis >50% of the total lesion. This is not a full list of criteria.

eyeball
eyeball
eyeball
eyeball

FAQ’s

What is the primary objective of the EYP-1901-302 study?

To evaluate the efficacy of EYP-1901 intravitreal (IVT) insert on best corrected visual acuity (BCVA) changes compared to aflibercept treatment.

What is the study drug being evaluated in the EYP-1901-302 study?

EYP-1901 (vorolanib intravitreal [IVT] insert)

If my patient qualifies for the EYP-1901-302 study, will they receive the study drug?

Participants will be randomly assigned to one of two treatment groups: EYP-1901 or aflibercept.

How many participants will be in this study?

Approximately 400 participants will be enrolled.